Krystal Biotech Inc reports results for the quarter ended in March - Earnings Summary

Krystal Biotech

08/05/2023 13:44

* Krystal Biotech Inc  KRYS.OQ  reported a quarterly
adjusted loss
of $1.76​​ per share for the quarter ended in March. The mean
expectation of seven analysts for the quarter was for a loss of
$1.44 per share.
    * Reported revenue was zero​; analysts expected $200.00
thousand. 
    * Krystal Biotech Inc's reported EPS for the quarter was a
loss of
$1.76​.
    * The mean earnings estimate of analysts had fallen by
about 97.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Krystal Biotech Inc shares had risen by 5.2% this
quarter and
gained 6.3% so far this year.
    * The company reported a quarterly loss of $45.3 million.
    * Wall Street's median 12-month price target for Krystal
Biotech
Inc is $108.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 12:44 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.44          -1.76          Missed
 Dec. 31 2022      -1.32          -1.25          Beat
 Sep. 30 2022      -1.22          -1.17          Beat
 Jun. 30 2022      -1.02          -1.10          Missed